These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 30352678)

  • 1. Synthetically Lethal Interactions of ATM, ATR, and DNA-PKcs.
    Kantidze OL; Velichko AK; Luzhin AV; Petrova NV; Razin SV
    Trends Cancer; 2018 Nov; 4(11):755-768. PubMed ID: 30352678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA-PKcs, ATM, and ATR Interplay Maintains Genome Integrity during Neurogenesis.
    Enriquez-Rios V; Dumitrache LC; Downing SM; Li Y; Brown EJ; Russell HR; McKinnon PJ
    J Neurosci; 2017 Jan; 37(4):893-905. PubMed ID: 28123024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATR-dependent phosphorylation of DNA-dependent protein kinase catalytic subunit in response to UV-induced replication stress.
    Yajima H; Lee KJ; Chen BP
    Mol Cell Biol; 2006 Oct; 26(20):7520-8. PubMed ID: 16908529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage.
    Falck J; Coates J; Jackson SP
    Nature; 2005 Mar; 434(7033):605-11. PubMed ID: 15758953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function.
    Menezes DL; Holt J; Tang Y; Feng J; Barsanti P; Pan Y; Ghoddusi M; Zhang W; Thomas G; Holash J; Lees E; Taricani L
    Mol Cancer Res; 2015 Jan; 13(1):120-9. PubMed ID: 25232030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
    Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ
    Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic Lethality through the Lens of Medicinal Chemistry.
    Myers SH; Ortega JA; Cavalli A
    J Med Chem; 2020 Dec; 63(23):14151-14183. PubMed ID: 33135887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors.
    Riabinska A; Daheim M; Herter-Sprie GS; Winkler J; Fritz C; Hallek M; Thomas RK; Kreuzer KA; Frenzel LP; Monfared P; Martins-Boucas J; Chen S; Reinhardt HC
    Sci Transl Med; 2013 Jun; 5(189):189ra78. PubMed ID: 23761041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ATM and Rad3-Related (ATR) Protein Kinase Pathway Is Activated by Herpes Simplex Virus 1 and Required for Efficient Viral Replication.
    Edwards TG; Bloom DC; Fisher C
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the replication stress response through synthetic lethal strategies in cancer medicine.
    Ngoi NYL; Pham MM; Tan DSP; Yap TA
    Trends Cancer; 2021 Oct; 7(10):930-957. PubMed ID: 34215565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replication protein A2 phosphorylation after DNA damage by the coordinated action of ataxia telangiectasia-mutated and DNA-dependent protein kinase.
    Wang H; Guan J; Wang H; Perrault AR; Wang Y; Iliakis G
    Cancer Res; 2001 Dec; 61(23):8554-63. PubMed ID: 11731442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting DNA repair mechanisms in cancer.
    Furgason JM; Bahassi el M
    Pharmacol Ther; 2013 Mar; 137(3):298-308. PubMed ID: 23107892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
    Bradbury A; Hall S; Curtin N; Drew Y
    Pharmacol Ther; 2020 Mar; 207():107450. PubMed ID: 31836456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both ATM and DNA-PK Are the Main Regulators of HIV-1 Post-Integrational DNA Repair.
    Anisenko A; Nefedova A; Agapkina Y; Gottikh M
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of ataxia telangiectasia mutated kinase inhibitors.
    Andrs M; Korabecny J; Nepovimova E; Jun D; Hodny Z; Moravcova S; Hanzlikova H; Kuca K
    Mini Rev Med Chem; 2014; 14(10):805-11. PubMed ID: 25138084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA-activated protein kinase functions in a newly observed S phase checkpoint that links histone mRNA abundance with DNA replication.
    Müller B; Blackburn J; Feijoo C; Zhao X; Smythe C
    J Cell Biol; 2007 Dec; 179(7):1385-98. PubMed ID: 18158334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors.
    Job A; Schmitt LM; von Wenserski L; Lankat-Buttgereit B; Gress TM; Buchholz M; Gallmeier E
    Neoplasia; 2018 Nov; 20(11):1135-1143. PubMed ID: 30257222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Potentials of DNA-PKcs, Ku80, and ATM in enhancing radiosensitivity of cervical carcinoma cells].
    Zhuang L; Yu SY; Huang XY; Cao Y; Xiong HH
    Ai Zheng; 2007 Jul; 26(7):724-9. PubMed ID: 17626748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATM and ATR as therapeutic targets in cancer.
    Weber AM; Ryan AJ
    Pharmacol Ther; 2015 May; 149():124-38. PubMed ID: 25512053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA damage sensors ATM, ATR, DNA-PKcs, and PARP-1 are dispensable for human immunodeficiency virus type 1 integration.
    Ariumi Y; Turelli P; Masutani M; Trono D
    J Virol; 2005 Mar; 79(5):2973-8. PubMed ID: 15709017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.